CD37 and peripheral T-cell lymphoma, not otherwise specified: While CD37 is predominantly being examined for dual targeting for B cell malignancies, the expression of CD37 in some cases of CTCL and peripheral T cell lymphoma (PTCL) makes it an attractive target in these malignancies, otherwise difficult to treat with CAR-T cell-based therapies.